<i>BRCA</i> and Beyond: Impact on Therapeutic Choices Across Cancer.

Cancers (Basel) · 2024 · PMC11718952 · PMID 39796639

Europe PMC DOI

hedged sentence

0.5130

closest p · 10.3× alpha

0.5130

boldest claim

The sentences

a numerical trendp = 0.513not close (p > 0.1)

While there was a numerical trend towards OS benefit with olaparib (median OS 19.3 months versus 17.1 months), this was not statistically significant (HR 0.90; 95% CI 0.66–1.23; p = 0.513) [ 6 ].

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.